FDA Advisory Committee Approves Zevra Therapeutics’ Arimoclomol for Rare Genetic Disease Treatment
Zevra Therapeutics, Arimoclomol, FDA Advisory Committee, Niemann-Pick disease, rare genetic disease, drug approval
Kyowa Kirin Divests China Unit and Reduces Small-Molecule Discovery Efforts
Kyowa Kirin, China business, small-molecule discovery, restructuring, Asia Pacific, pharmaceuticals
Galapagos Halts BCMA CAR-T Study Due to Parkinsonism Case
Galapagos, BCMA CAR-T, Parkinsonism, multiple myeloma, CAR-T therapy, clinical trial, PAPILIO-1 study, GLPG5301
Accelerating Sales of Eisai and Biogen’s Alzheimer’s Drug Leqembi in Japan
Leqembi, Alzheimer’s drug, Eisai, Biogen, Japan, sales acceleration
23andMe Board Rejects CEO Anne Wojcicki’s Take-Private Plan, Requests Changes
23andMe, Anne Wojcicki, take-private plan, board rejection, financing, stock price, shareholders
Novartis Intensifies Entresto Defense with FDA Complaint Amid Patent Lawsuits
Novartis, Entresto, FDA complaint, patent lawsuits, pharmaceuticals
Agios’ Pyrukynd Misses Primary Endpoint in First Pediatric Study for Rare Blood Disorder
Agios Pharmaceuticals, Pyrukynd, mitapivat, PK deficiency, pediatric study, blood disorder, Phase 3 ACTIVATE-KidsT study
Vir Biotechnology Acquires T-Cell Engagers from Sanofi, Reduces Staff by 25% in Strategic Pipeline Shift
Vir Biotechnology, Sanofi, T-cell engagers, pipeline switch-up, staff reduction, biotech industry, pharmaceuticals
Impact of New CDC Guidelines on RSV Vaccine Makers
RSV vaccine, CDC guidelines, vaccine makers, Moderna, Pfizer, GSK, Guillain-Barré syndrome, vaccination recommendations